Megan Sullivan, MD
Rheumatology · Scottsdale, AZNPI 1841726759
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,248 of the $3,360 with a category attached, or 66.9%. 9 manufacturers reported payments, led by Amgen at 59.1% of the total. Reporting peaked in 2023 at $1,454 and has fallen 80.1% since, to $290 in 2025. That places this record below the midpoint for rheumatology clinicians in AZ, where the typical reported total is $3,203.
Across 29 payments — averaging $115.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Aurinia Pharma U.S., Inc.$350
- Sanofi$294
- AstraZeneca$250
- Novartis$138
- Lilly USA, LLC$119
- plus $223 from 3 others
What the payments were for
- Consulting fees$1,00030%
- Food & beverage$2,24867%
- Education$1123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 10 | $1,987 |
| Aurinia Pharma U.S., Inc. | 6 | $350 |
| Sanofi | 3 | $294 |
| AstraZeneca(2 entities) | 3 | $250 |
| Novartis | 3 | $138 |
| Lilly USA, LLC | 1 | $119 |
| UCB, Inc. | 1 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $92 |
| Echosens North America, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,360 in reported general payments places this provider in the 50th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 140 | $1,473 |
| MethotrexateMethotrexate Sodium | 49 | $1,166 |
| Hydroxychloroquine Sulfate | 33 | $801 |
| Sulfasalazine DrSulfasalazine | 11 | $313 |
| Folic Acid | 13 | $168 |
| Allopurinol | 15 | $117 |
| Methylprednisolone | 11 | $98 |
| Alendronate Sodium | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Scottsdale
- Paul HowardScottsdale$124K
- Vivek NagarajaScottsdale$36K
- Ramin SabahiScottsdale$13K
- Gabriel ColceriuScottsdale$13K
- Hani RashidScottsdale$13K
- Mark FreijatScottsdale$10K
- Lester MertzScottsdale$4K
- Fawad AslamScottsdale$3K
- Winford GriffingScottsdale$2K
- Nehad SolomanPhoenix$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.